Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · CAPLIPOINT

CAPLIPOINT

HealthcarePharmaceuticals & Biotechnology₹15853 cr market cap
₹2091.50 ▲ +0.3% today As of 19 Nov 2026
52-week low ₹1504.8052-week high ₹2867.40

-27.3% from the 52-week high · +38.6% above the low

Caplin Point Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Chennai, Tamil Nadu and currently employs 777 full-time employees. The firm is engaged in producing, developing, and marketing a range of generic formulations and branded products and exporting to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injection in ampoules and vials, ophthalmic droppers, pre-mix bags, topicals and sachets (liquids and powders). The company also manufactures a range of ointments, creams, gels and lotions. Its principal research and development facilities are in Tamil Nadu, India. Its principal manufacturing facility is in Puducherry, India. The company has presence in Latin America (LATAM), Southern Africa and Francophone Africa along with a presence in United States of America and European region. The Company’s subsidiaries include Caplin Point Far East Limited and Caplin Steriles Limited.

The short version. CAPLIPOINT reported revenue of ₹630 crore for Sep 2026, up 18.0% from a year earlier. Net profit was ₹178 crore (up 15.6% year on year). Return on equity was 17.9% in Mar 2026. Promoter holding was 70.57% in Sep 2026, up 0.01 points over 8 quarters.

1 · The price

How has the stock traded?

CAPLIPOINT trades 27.3% below its 52-week high and 38.6% above its 52-week low.

Change over period: —

1M-7.7%
3M-18.9%
6M+3.4%
1Y+8.9%

2 · The business

Is it growing?

Sales, year on year+18.0%

Sep 2026 revenue of ₹630 cr.

Profit, year on year+15.6%

Sep 2026 net profit of ₹178 cr.

Net margin28.3%

0.6 pts lower than a year earlier.

3-year growth19.4% profit

Revenue compounded at 14.8% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue630610600543534510502493
Net profit178177170164154153143139
Net margin %28.329.028.330.228.929.928.428.2
EPS (₹)23.4323.2722.3821.5620.3220.118.7618.28

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue218719371694146712691061863649
Net profit641536457376308242215177
Net margin %29.327.727.025.724.322.824.927.2
EPS (₹)84.3670.5660.1949.5740.732.0328.4223.35

3 · The quality

How well does it turn capital into profit?

Return on equity was 17.9% in Mar 2026; debt to equity is 0.00.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %17.918.819.720.0
Return on capital %22.023.323.923.5
EBITDA margin %38.136.535.132.6
Net margin %27.926.426.024.7

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR14.8%16.2%
Profit CAGR19.4%21.5%
Debt to equity0.00
Interest cover923.8x
Current ratio6.70
P/E ratio23.1

4 · The owners

Who holds it, and are they adding?

Promoter holding70.57%

Up 0.01 pts over 8 quarters.

Foreign institutions5.73%

Up 0.87 pts over 8 quarters.

Domestic institutions2.2%

Up 0.09 pts over 8 quarters.

Mutual fund schemes67

+16 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter70.5670.5670.5670.5770.5770.5770.5770.57+0.01
FII4.865.736.176.516.596.155.755.73+0.87
DII2.112.012.222.12.052.142.492.2+0.09
Public22.4721.721.0520.8220.7921.1421.1821.5-0.97

Mutual fund holdings · Oct 2026

67 schemes hold this stock

51 the month before.

  • UTI - Healthcare Fund2.68% of NAV
  • THE WEALTH COMPANY SMALL CAP FUND1.7% of NAV
  • THE WEALTH COMPANY BALANCED ADVT FUND1.64% of NAV
  • UTI Small Cap Fund1.61% of NAV
  • the Quantum Small Cap Fund1.56% of NAV
  • UTI Large & Mid Cap Fund0.93% of NAV
  • UTI Aggressive Hybrid Fund0.7% of NAV
  • Groww Nifty Smallcap 250Mom Qlty 100 ETF0.64% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for CAPLIPOINT are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about CAPLIPOINT

What is the CAPLIPOINT share price?

CAPLIPOINT (CAPLIPOINT) last closed at ₹2,091.50, up 0.3% on the day. Its 52-week range is ₹1,504.80 to ₹2,867.40.

What is the market cap of CAPLIPOINT?

CAPLIPOINT has a market capitalisation of about ₹15,853 crore. Its price-to-earnings ratio is 23.1.

How are CAPLIPOINT's latest results?

CAPLIPOINT reported revenue of ₹630 crore for Sep 2026, up 18.0% from a year earlier. Net profit was ₹178 crore (up 15.6% year on year). Return on equity was 17.9% in Mar 2026. Promoter holding was 70.57% in Sep 2026, up 0.01 points over 8 quarters.

Who owns CAPLIPOINT?

As of Sep 2026, shareholding was: Promoter 70.57%, FII 5.73%, DII 2.2%, Public 21.5%.

How many mutual funds hold CAPLIPOINT?

67 mutual fund schemes held CAPLIPOINT in October 2026. That compares with 51 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 29 May 2026 · Interim Dividend - Rs. 4
  • 12 Sep 2025 · Final Dividend - Rs. 3
  • 30 May 2025 · Interim Dividend - Rs. 3
  • 23 Sep 2024 · Final Dividend - Rs. 2.5
  • 31 May 2024 · Interim Dividend - Rs. 2.5
  • 14 Sep 2023 · Final Dividend - Rs. 2.5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.